544467-05-2

Basic information

• Product Name: 1-(3-(azidomethyl) phenyl) ethanone
• Synonyms: 1-(3-(azidomethyl) phenyl) ethanone
• CAS NO: 544467-05-2
• Molecular Weight: 175.19
• Mol File: 544467-05-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1-(3-(azidomethyl) phenyl) ethanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-(azidomethyl) phenyl) ethanone(544467-05-2)
• EPA Substance Registry System: 1-(3-(azidomethyl) phenyl) ethanone(544467-05-2)

Safety Data

• Hazardous Substances Data: 544467-05-2(Hazardous Substances Data)

Upstream product

• 585-74-0 3-Methylacetophenone 
• 75369-41-4 1-[3-(bromomethyl)phenyl]ethan-1-one 

Downstream Products

• 1242879-48-6 tert-butyl 3-acetylbenzylcarbamate 
• 839726-53-3 1-[3-(benzylamino-methyl)-phenyl]-ethanone 
• 1263183-66-9 C₁₈H₁₇NO₂ 
• 103-29-7 1,1'-(1,2-ethanediyl)bisbenzene 
• 748104-67-8 1-(3-(aminomethyl)phenyl)ethanone 
• 41908-11-6 3-acetylbenzaldehyde 
• 6136-68-1 3-acethylbenzonitrile 
• 1263183-73-8 1-{3[5-(3-acetylphenyl)-[1,2,4]oxadiazol-3-yl]-phenyl}ethanone 

Relevant articles and documents

INHIBITORS OF HEPATITIS C VIRUS POLYMERASE

The present invention provides, among other things, compounds represented by the general Formula I: (I) and pharmaceutically acceptable salts thereof, wherein L and A (and further substituents) are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.

Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same

The invention relates to substituted isoxazolines according to the general formula (I) : in which A, R1, R2, R3, R4, Z, X, m, n, and p, are given in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted isoxazolines, to methods of preparing said substituted isoxazolines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases known to be at least in part mediated by HDAC activity or whose symptoms are known to be alleviated by HDAC inhibitors.